Statin-fibrate combination for mixed dyslipidaemia: A limited option

Current Medical Research and Opinion

Volumn 26, Issue 9, 2010, Pages 2137-2140

  Athyros, Vasilios G ^a   Tziomalos, Konstantinos ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Clinical outcome; Efficacy; Fibrate; Mixed dyslipidaemia; Safety; Statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE CONTROL; DRUG DOSE REGIMEN; DRUG SAFETY; DYSLIPIDEMIA; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MIXED DYSLIPIDEMIA; MONOTHERAPY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; THERAPY EFFECT; VEIN THROMBOSIS;

CHOICE BEHAVIOR; DRUG COMBINATIONS; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS;

EID: 77955611158     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.505463     Document Type: Review

References (30)

1. Genest Jr JJ, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-2033
2. Tziomalos K, Athyros VG, Karagiannis A, et al. Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets 2009;10:320-327
3. Chait A, Brazg RL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-356
4. Austin MA, Breslow JL, Hennekens CH, et al. Low density lipoprotein subclass patters and risk of myocardial infarction. JAMA 1988;260:1917-1921
5. Tornvall P, Ba° venholm P, Landou C, et al. Relation of plasma levels of apoprotein B-containing lipoproteins angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993;88:2180-2189
6. Assmann G, Schulte H. Identification of individuals at high risk for myocardial infarction. Atherosclerosis 1994;110(Suppl.):11S-21S
7. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk 1995;2:197-205
8. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71-75
9. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003;19:155-168
10. Kontopoulos AG, Athyros VG, Papageorgiou AA, et al. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis 1996;7:843-850
11. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997;80:608-613
12. Athyros VG, Papageorgiou AA, Kontopoulos AG. Statin-fibrate combinations in patients with combined hyperlipidemia. Atherosclerosis 2001;155:263-264
13. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. J Cardiovasc Risk 2002;9:33-39
14. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-1202
15. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005;54:1065-1074
16. Wierzbicki AS, Morrell J, Hemsley D, et al. The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis. Curr Med Res Opinion 2010;13:2141-2146
17. Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009;151:622-630
18. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435
19. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
20. Fruchart JC, Sacks FM, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes Vasc Dis Res 2008;5:319-335
21. Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
22. Simes J, Voysey M, O'Connell R, et al. FIELD Study Investigators. A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PLoS One 2010;5:e8580
23. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
24. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45
25. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-27
26. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239
27. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92
28. Asztalos BF, Collins D, Horvath KV, et al. Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism 2008;57:77-83
29. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-458
30. Papadakis JA, Ganotakis ES, Jagroop IA, et al. Statin\+fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 1999;69:237-244